Ronald H. P. Brus
Chief Executive Officer bij Janssen Vaccines & Prevention BV
Profiel
Ronald H.
P.
Brus is the founder of Impatients NV, where he holds the title of Co-Chief Executive Officer since 2012.
He is also the founder of Leyden Laboratories B.V.
Dr. Brus's current job is as the President & Chief Executive Officer at Janssen Vaccines & Prevention BV.
Dr. Brus's former jobs include being the Chairman-Management Board, President & CEO at Crucell NV, a Non-Executive Director at Galapagos NV, and a Medical Director at Zambon Nederland BV.
Dr. Brus obtained his undergraduate and doctorate degrees from the University of Groningen in 2010.
Actieve functies van Ronald H. P. Brus
Bedrijven | Functie | Begin |
---|---|---|
Janssen Vaccines & Prevention BV
Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands. | Chief Executive Officer | 20-04-2011 |
Impatients NV
Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | Chief Executive Officer | 01-01-2012 |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Founder | - |
Eerdere bekende functies van Ronald H. P. Brus
Bedrijven | Functie | Einde |
---|---|---|
GALAPAGOS NV | Director/Board Member | 25-05-2011 |
Zambon Nederland BV
Zambon Nederland BV Pharmaceuticals: MajorHealth Technology Zambon Nederland BV operates as a pharmaceutical company. The company was founded in 1906 and is headquartered in Amersfoort, the Netherlands. | Corporate Officer/Principal | 01-01-1994 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Chief Executive Officer | - |
Opleiding van Ronald H. P. Brus
University of Groningen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
GALAPAGOS NV | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |
Janssen Vaccines & Prevention BV
Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands. | Health Technology |
Zambon Nederland BV
Zambon Nederland BV Pharmaceuticals: MajorHealth Technology Zambon Nederland BV operates as a pharmaceutical company. The company was founded in 1906 and is headquartered in Amersfoort, the Netherlands. | Health Technology |
Impatients NV
Impatients NV Miscellaneous Commercial ServicesCommercial Services Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom. | Commercial Services |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Commercial Services |